Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

BACKGROUND: Most patients treated with anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitors for ALK‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous system (CNS) being a primary concern. Although alectinib has bette...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Hiroaki, Yanagitani, Noriko, Manabe, Ryo, Tsugitomi, Ryosuke, Ogusu, Shinsuke, Tozuka, Takehiro, Yoshida, Hiroshi, Amino, Yoshiaki, Ariyasu, Ryo, Uchibori, Ken, Kitazono, Satoru, Tasaka, Sadatomo, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714545/
https://www.ncbi.nlm.nih.gov/pubmed/33960745
http://dx.doi.org/10.1002/cnr2.1414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714545/
https://www.ncbi.nlm.nih.gov/pubmed/33960745
http://dx.doi.org/10.1002/cnr2.1414

Ejemplares similares